Nephros vs Nexgel
NEPH and NXGL side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NEPH and NXGL compare
Nexgel is the larger company, worth 1.2 times as much as Nephros ($37.0M against $31.5M).
Nephros grew revenue faster over the last twelve months (24.2% versus 3.4% for Nexgel).
Nephros keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with −51.3% at Nexgel.
Nephros scores higher on the StockData Score (13 against 6 for Nexgel), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NEPH | NXGL |
|---|---|---|
| Size and price | ||
| Market cap | $31.5M | $37.0M |
| Share price | $2.90 | $3.80 |
| Change, 1 year | −34.1% | −90.1% |
| Change, 5 years | −59.6% | – |
| Beta (5Y) | 1.75 | 1.08 |
| Employees | 36 | 19 |
| StockData Score | ||
| Total score | 13 (better) | 6 |
| Valuation score | 4 (better) | 2 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 18.1× | – |
| P/S | 1.5× (better) | 3.1× |
| P/B | – | 7.5× |
| EV/EBITDA | 15.2× | – |
| Fair value | $3.74 | $12.33 |
| Margin of safety | 22.5% | 69.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 24.2% (better) | 3.4% |
| Revenue growth, 5Y average | 17.0% | 76.1% (better) |
| Net income growth (TTM) | 30.8% | – |
| EPS growth (TTM) | 33.3% | – |
| Profitability | ||
| Gross margin | 61.3% (better) | 35.1% |
| Operating margin | 7.9% (better) | −44.8% |
| Net margin | 8.4% (better) | −51.3% |
| Return on equity | – | −129% |
| Return on invested capital | – | −91.0% |
| Financial health | ||
| Debt / equity | – | 0.09 |
| Current ratio | 4.07 (better) | 0.43 |
| Altman Z-score | −5.18 | −0.89 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 48.9% | 9.0% |
| Held by insiders | 9.5% | 13.2% |
| Insider net buying, 12 months | – | $721K |
| Short interest, % of float | 0.12% | – |
Go deeper
- NEPH stock overview
- NEPH income statement
- NEPH valuation and score
- NXGL stock overview
- NXGL income statement
- NXGL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.